Higher Crohn's disease rates with vedolizumab: a study

Published Date: 13 Mar 2023

The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.

Read Full News

Latest News

SIBO Tied to Higher Bile Acid Synthesis in Patients With Chronic Diarrhea

SIBO Tied to Higher Bile Acid Synthesis in Patients With Chronic Diarrhea

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial Evan Dellon, MD, MPH

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Fertility Treatment in IBD: Insights From the WIsDoM Cohort Eugenia Shmidt, MD, Zoë Gottlieb, MD

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD David Rubin, MD

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Latest News

SIBO Tied to Higher Bile Acid Synthesis in Patients With Chronic Diarrhea

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

News All Time

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A Alex Hillenbrand

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

Obefazimod Delivers Week 44 Remission in Refractory UC Patients Alex Hillenbrand

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

The HCPFive: Top News for Healthcare Providers from the Week of 06/21 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs Brian Lacy, MD, PhD

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

When Abdominal Pain Is Actually a Food Allergy: A GI Workup Brian Lacy, MD, PhD

Brian Lacy, MD, PhD, of Mayo Clinic discussed the stepwise approach to diagnosing non-IgE mediated food hypersensitivity at EAC 2026.

First Half 2026 Recap: Gastroenterology Alex Hillenbrand

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

Recommended News For You

Top 10 questions about breast cancer answered

Smart exercise planning could boost recovery for people with cancer

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

Recommended Articles For You

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians 

Comprehensive Breakthroughs in Oncology for Better Care 

The Different Types of Cysts and Why They Occur: Insights from a Dermatologist  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD

2.

How the skin cancer virus outperforms the replication of host cells.

3.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

4.

Housing aid linked to lower medical financial hardship among US renters with cancer

5.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

1.

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment

2.

Intensive Care Challenges in Advanced Cancer

3.

Childhood Cancer Survivorship and Long-Term Organ Health

4.

Guideline Evolution in Benign Hematologic Conditions

5.

The Latest Research on Wiskott Aldrich Syndrome 

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

3.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

5.

Navigating the Complexities of Ph Negative ALL - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot